Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03883516
Other study ID # Requ_2019-00168; me19Sutter3
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 30, 2019
Est. completion date December 2024

Study information

Verified date April 2024
Source University Hospital, Basel, Switzerland
Contact Raoul Sutter, PD Dr. MD
Phone +41 61 328 79 28
Email raoul.sutter@usb.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the trial the effectiveness of pre-briefing physicians with the current guideline on Status epilepticus (SE) treatment or a consolidated "one page" guideline regarding quality enhancement of the physician's clinical performances is investigated.


Description:

Status epilepticus (SE) is a life-threatening neurological emergency defined as a state of continuous seizure or multiple seizures without full recovery of sensory, motor and/or cognitive function for at least 30 minutes. To achieve high quality management of SE, the American Epilepsy Society published an evidence-based guideline for the treatment of SE, which serves as reference for most national guidelines, but analyses regarding practicability, strict adherence, correct translation into clinical practice, and identification of recommended treatment steps at risk of being modified or missed are lacking. Simulator-based studies offer a platform for the design of standardized clinical scenarios that enable detailed investigations regarding the effect of the implementation and practicability of treatment guidelines. This randomized controlled intervention study performed at the simulation center of the medical intensive care units (ICUs) at the University Hospital Basel is to investigate the effectiveness of pre-briefing physicians with both the current guideline on Status epilepticus (SE) treatment or a consolidated "one page" guideline regarding quality enhancement of the physicians' clinical performances.. Physicians from different medical specialties and with different duration of clinical experience will be enrolled. Participants will be randomly assigned to one of the following three pre-briefing groups: (1) no pre-briefing prior to the simulation training; (2) pre-briefing with the current SE treatment guidelines; (3) pre-briefing with the consolidated "one page" SE treatment guideline.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Physicians from different medical specialties working at the University Hospital Basel Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pre-briefing with the current SE treatment guidelines
instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
Pre-briefing with a consolidated "one page" SE treatment guide
instruction of the study participants with a consolidated "one page" SE treatment guide prior to the simulation training
No Pre-briefing
no instruction of the study participants prior to the simulation training

Locations

Country Name City State
Switzerland Clinic for Intensive Care Medicine, University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to SE recognition (minutes) time to recognition of seizure and/or SE from start of simulation training until recognition of seizure and/or SE (max. 20 minutes)
Secondary administration of anti-seizure medication time of administration of anti-seizure medication (minutes) within the first 20 minutes after beginning of the simulation training
Secondary dose of anti-seizure medication dose of anti-seizure medication (mg) within the first 20 minutes after beginning of the simulation training
Secondary time to correct airways protection time to correct airways protection (minutes) from start of simulation training until correct airways protection (max. 20 minutes)
Secondary quantification of Glasgow Coma Score (GCS) GCS is a neurological scale recording the state of a person's consciousness ; The scale is composed of three tests: eye, verbal and motor responses. The three values separately as well as their sum are considered. The lowest possible GCS (graded 1 in each element) is 3 (deep coma or death), while the highest is 15 (fully awake person). within the first 20 minutes after beginning of the simulation training
See also
  Status Clinical Trial Phase
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Active, not recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Recruiting NCT06401707 - PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Phase 2
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4
Recruiting NCT05246566 - Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana